Pathway analysis of kidney cancer using proteomics and metabolic profiling

Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US. Approximately one-third of patients present with disease which is already metastatic and for which there is currently no adequate treatment, and no biofluid screening tests...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 5; no. 1; p. 64
Main Authors Perroud, Bertrand, Lee, Jinoo, Valkova, Nelly, Dhirapong, Amy, Lin, Pei-Yin, Fiehn, Oliver, Kültz, Dietmar, Weiss, Robert H
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 24.11.2006
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US. Approximately one-third of patients present with disease which is already metastatic and for which there is currently no adequate treatment, and no biofluid screening tests exist for RCC. In this study, we have undertaken a comprehensive proteomic analysis and subsequently a pathway and network approach to identify biological processes involved in clear cell RCC (ccRCC). We have used these data to investigate urinary markers of RCC which could be applied to high-risk patients, or to those being followed for recurrence, for early diagnosis and treatment, thereby substantially reducing mortality of this disease. Using 2-dimensional electrophoresis and mass spectrometric analysis, we identified 31 proteins which were differentially expressed with a high degree of significance in ccRCC as compared to adjacent non-malignant tissue, and we confirmed some of these by immunoblotting, immunohistochemistry, and comparison to published transcriptomic data. When evaluated by several pathway and biological process analysis programs, these proteins are demonstrated to be involved with a high degree of confidence (p values < 2.0 E-05) in glycolysis, propanoate metabolism, pyruvate metabolism, urea cycle and arginine/proline metabolism, as well as in the non-metabolic p53 and FAS pathways. In a pilot study using random urine samples from both ccRCC and control patients, we performed metabolic profiling and found that only sorbitol, a component of an alternative glycolysis pathway, is significantly elevated at 5.4-fold in RCC patients as compared to controls. Extensive pathway and network analysis allowed for the discovery of highly significant pathways from a set of clear cell RCC samples. Knowledge of activation of these processes will lead to novel assays identifying their proteomic and/or metabolomic signatures in biofluids of patient at high risk for this disease; we provide pilot data for such a urinary bioassay. Furthermore, we demonstrate how the knowledge of networks, processes, and pathways altered in kidney cancer may be used to influence the choice of optimal therapy.
AbstractList Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US. Approximately one-third of patients present with disease which is already metastatic and for which there is currently no adequate treatment, and no biofluid screening tests exist for RCC. In this study, we have undertaken a comprehensive proteomic analysis and subsequently a pathway and network approach to identify biological processes involved in clear cell RCC (ccRCC). We have used these data to investigate urinary markers of RCC which could be applied to high-risk patients, or to those being followed for recurrence, for early diagnosis and treatment, thereby substantially reducing mortality of this disease. Using 2-dimensional electrophoresis and mass spectrometric analysis, we identified 31 proteins which were differentially expressed with a high degree of significance in ccRCC as compared to adjacent non-malignant tissue, and we confirmed some of these by immunoblotting, immunohistochemistry, and comparison to published transcriptomic data. When evaluated by several pathway and biological process analysis programs, these proteins are demonstrated to be involved with a high degree of confidence (p values < 2.0 E-05) in glycolysis, propanoate metabolism, pyruvate metabolism, urea cycle and arginine/proline metabolism, as well as in the non-metabolic p53 and FAS pathways. In a pilot study using random urine samples from both ccRCC and control patients, we performed metabolic profiling and found that only sorbitol, a component of an alternative glycolysis pathway, is significantly elevated at 5.4-fold in RCC patients as compared to controls. Extensive pathway and network analysis allowed for the discovery of highly significant pathways from a set of clear cell RCC samples. Knowledge of activation of these processes will lead to novel assays identifying their proteomic and/or metabolomic signatures in biofluids of patient at high risk for this disease; we provide pilot data for such a urinary bioassay. Furthermore, we demonstrate how the knowledge of networks, processes, and pathways altered in kidney cancer may be used to influence the choice of optimal therapy.
Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US. Approximately one-third of patients present with disease which is already metastatic and for which there is currently no adequate treatment, and no biofluid screening tests exist for RCC. In this study, we have undertaken a comprehensive proteomic analysis and subsequently a pathway and network approach to identify biological processes involved in clear cell RCC (ccRCC). We have used these data to investigate urinary markers of RCC which could be applied to high-risk patients, or to those being followed for recurrence, for early diagnosis and treatment, thereby substantially reducing mortality of this disease.BACKGROUNDRenal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US. Approximately one-third of patients present with disease which is already metastatic and for which there is currently no adequate treatment, and no biofluid screening tests exist for RCC. In this study, we have undertaken a comprehensive proteomic analysis and subsequently a pathway and network approach to identify biological processes involved in clear cell RCC (ccRCC). We have used these data to investigate urinary markers of RCC which could be applied to high-risk patients, or to those being followed for recurrence, for early diagnosis and treatment, thereby substantially reducing mortality of this disease.Using 2-dimensional electrophoresis and mass spectrometric analysis, we identified 31 proteins which were differentially expressed with a high degree of significance in ccRCC as compared to adjacent non-malignant tissue, and we confirmed some of these by immunoblotting, immunohistochemistry, and comparison to published transcriptomic data. When evaluated by several pathway and biological process analysis programs, these proteins are demonstrated to be involved with a high degree of confidence (p values < 2.0 E-05) in glycolysis, propanoate metabolism, pyruvate metabolism, urea cycle and arginine/proline metabolism, as well as in the non-metabolic p53 and FAS pathways. In a pilot study using random urine samples from both ccRCC and control patients, we performed metabolic profiling and found that only sorbitol, a component of an alternative glycolysis pathway, is significantly elevated at 5.4-fold in RCC patients as compared to controls.RESULTSUsing 2-dimensional electrophoresis and mass spectrometric analysis, we identified 31 proteins which were differentially expressed with a high degree of significance in ccRCC as compared to adjacent non-malignant tissue, and we confirmed some of these by immunoblotting, immunohistochemistry, and comparison to published transcriptomic data. When evaluated by several pathway and biological process analysis programs, these proteins are demonstrated to be involved with a high degree of confidence (p values < 2.0 E-05) in glycolysis, propanoate metabolism, pyruvate metabolism, urea cycle and arginine/proline metabolism, as well as in the non-metabolic p53 and FAS pathways. In a pilot study using random urine samples from both ccRCC and control patients, we performed metabolic profiling and found that only sorbitol, a component of an alternative glycolysis pathway, is significantly elevated at 5.4-fold in RCC patients as compared to controls.Extensive pathway and network analysis allowed for the discovery of highly significant pathways from a set of clear cell RCC samples. Knowledge of activation of these processes will lead to novel assays identifying their proteomic and/or metabolomic signatures in biofluids of patient at high risk for this disease; we provide pilot data for such a urinary bioassay. Furthermore, we demonstrate how the knowledge of networks, processes, and pathways altered in kidney cancer may be used to influence the choice of optimal therapy.CONCLUSIONExtensive pathway and network analysis allowed for the discovery of highly significant pathways from a set of clear cell RCC samples. Knowledge of activation of these processes will lead to novel assays identifying their proteomic and/or metabolomic signatures in biofluids of patient at high risk for this disease; we provide pilot data for such a urinary bioassay. Furthermore, we demonstrate how the knowledge of networks, processes, and pathways altered in kidney cancer may be used to influence the choice of optimal therapy.
BACKGROUND: Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US. Approximately one-third of patients present with disease which is already metastatic and for which there is currently no adequate treatment, and no biofluid screening tests exist for RCC. In this study, we have undertaken a comprehensive proteomic analysis and subsequently a pathway and network approach to identify biological processes involved in clear cell RCC (ccRCC). We have used these data to investigate urinary markers of RCC which could be applied to high-risk patients, or to those being followed for recurrence, for early diagnosis and treatment, thereby substantially reducing mortality of this disease. RESULTS: Using 2-dimensional electrophoresis and mass spectrometric analysis, we identified 31 proteins which were differentially expressed with a high degree of significance in ccRCC as compared to adjacent non-malignant tissue, and we confirmed some of these by immunoblotting, immunohistochemistry, and comparison to published transcriptomic data. When evaluated by several pathway and biological process analysis programs, these proteins are demonstrated to be involved with a high degree of confidence (p values < 2.0 E-05) in glycolysis, propanoate metabolism, pyruvate metabolism, urea cycle and arginine/proline metabolism, as well as in the non-metabolic p53 and FAS pathways. In a pilot study using random urine samples from both ccRCC and control patients, we performed metabolic profiling and found that only sorbitol, a component of an alternative glycolysis pathway, is significantly elevated at 5.4-fold in RCC patients as compared to controls. CONCLUSION: Extensive pathway and network analysis allowed for the discovery of highly significant pathways from a set of clear cell RCC samples. Knowledge of activation of these processes will lead to novel assays identifying their proteomic and/or metabolomic signatures in biofluids of patient at high risk for this disease; we provide pilot data for such a urinary bioassay. Furthermore, we demonstrate how the knowledge of networks, processes, and pathways altered in kidney cancer may be used to influence the choice of optimal therapy.
Abstract Background Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US. Approximately one-third of patients present with disease which is already metastatic and for which there is currently no adequate treatment, and no biofluid screening tests exist for RCC. In this study, we have undertaken a comprehensive proteomic analysis and subsequently a pathway and network approach to identify biological processes involved in clear cell RCC (ccRCC). We have used these data to investigate urinary markers of RCC which could be applied to high-risk patients, or to those being followed for recurrence, for early diagnosis and treatment, thereby substantially reducing mortality of this disease. Results Using 2-dimensional electrophoresis and mass spectrometric analysis, we identified 31 proteins which were differentially expressed with a high degree of significance in ccRCC as compared to adjacent non-malignant tissue, and we confirmed some of these by immunoblotting, immunohistochemistry, and comparison to published transcriptomic data. When evaluated by several pathway and biological process analysis programs, these proteins are demonstrated to be involved with a high degree of confidence (p values < 2.0 E-05) in glycolysis, propanoate metabolism, pyruvate metabolism, urea cycle and arginine/proline metabolism, as well as in the non-metabolic p53 and FAS pathways. In a pilot study using random urine samples from both ccRCC and control patients, we performed metabolic profiling and found that only sorbitol, a component of an alternative glycolysis pathway, is significantly elevated at 5.4-fold in RCC patients as compared to controls. Conclusion Extensive pathway and network analysis allowed for the discovery of highly significant pathways from a set of clear cell RCC samples. Knowledge of activation of these processes will lead to novel assays identifying their proteomic and/or metabolomic signatures in biofluids of patient at high risk for this disease; we provide pilot data for such a urinary bioassay. Furthermore, we demonstrate how the knowledge of networks, processes, and pathways altered in kidney cancer may be used to influence the choice of optimal therapy.
ArticleNumber 64
Author Valkova, Nelly
Weiss, Robert H
Fiehn, Oliver
Perroud, Bertrand
Dhirapong, Amy
Lee, Jinoo
Lin, Pei-Yin
Kültz, Dietmar
AuthorAffiliation 2 Animal Science, University of California, Davis, CA, USA
1 Genome Center, University of California, Davis, CA, USA
3 Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA, USA
4 Department of Veterans' Affairs Northern California Health Care System, Mather, CA, USA
AuthorAffiliation_xml – name: 1 Genome Center, University of California, Davis, CA, USA
– name: 2 Animal Science, University of California, Davis, CA, USA
– name: 4 Department of Veterans' Affairs Northern California Health Care System, Mather, CA, USA
– name: 3 Division of Nephrology, Department of Internal Medicine, University of California, Davis, CA, USA
Author_xml – sequence: 1
  givenname: Bertrand
  surname: Perroud
  fullname: Perroud, Bertrand
– sequence: 2
  givenname: Jinoo
  surname: Lee
  fullname: Lee, Jinoo
– sequence: 3
  givenname: Nelly
  surname: Valkova
  fullname: Valkova, Nelly
– sequence: 4
  givenname: Amy
  surname: Dhirapong
  fullname: Dhirapong, Amy
– sequence: 5
  givenname: Pei-Yin
  surname: Lin
  fullname: Lin, Pei-Yin
– sequence: 6
  givenname: Oliver
  surname: Fiehn
  fullname: Fiehn, Oliver
– sequence: 7
  givenname: Dietmar
  surname: Kültz
  fullname: Kültz, Dietmar
– sequence: 8
  givenname: Robert H
  surname: Weiss
  fullname: Weiss, Robert H
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17123452$$D View this record in MEDLINE/PubMed
BookMark eNp1ks9vFCEUx4mpsT_06tHMydvUYfbxYy4mTWNtmyb2UM8EGNhSGViBtdn_XqZba1fTE4Tv533eSx6HaC_EYBB6j7tjjDn9hIHRFsjAW9JSeIUOnh72nt330WHOd12HGWfwBu1jhvsFkP4AXV7LcnsvN40M0m-yy020zQ83BrNptAzapGadXVg2qxSLiZPTuaJjM5kiVfROz4F1viJv0WsrfTbvHs8j9P3sy83peXv17evF6clVqwjjpYUBGAdqe9UrCyNg2i0UAwlcUU0tNVZqRRV0BtRoNOlGNmpTATzUkNrFEbrYesco78QquUmmjYjSiYeHmJZCpuK0NwJTqgbekxFbAGVg4IRzyTAfsJWM8Or6vHWt1moytU8oSfod6W4S3K1Yxl-zmcCD4GQrUC6-INhNdJzEvBcx70UQQaE6Pj4OkeLPtclFTC5r470MJq6zoBwPlC9IBT88n_apy591VuB4C-gUc07G_kU6Mf-X_1vDPwXaFVlcnId1_qWy3-P1xVc
CitedBy_id crossref_primary_10_1007_s12272_021_01310_0
crossref_primary_10_1074_mcp_M900168_MCP200
crossref_primary_10_1186_s12885_016_2775_2
crossref_primary_10_1038_s41417_019_0078_x
crossref_primary_10_1186_1745_6150_7_44
crossref_primary_10_1021_pr800804d
crossref_primary_10_3389_fmolb_2022_837145
crossref_primary_10_3389_fsurg_2022_837848
crossref_primary_10_1002_jbt_21871
crossref_primary_10_1016_j_semnephrol_2019_12_003
crossref_primary_10_1158_0008_5472_CAN_11_3105
crossref_primary_10_1038_cr_2011_149
crossref_primary_10_1007_s13277_014_2694_2
crossref_primary_10_1002_jcb_24022
crossref_primary_10_1038_srep37275
crossref_primary_10_1021_pr100226m
crossref_primary_10_1039_c2mb05390j
crossref_primary_10_1097_01_XEJ_0000542227_68517_54
crossref_primary_10_1016_j_chemosphere_2019_04_111
crossref_primary_10_1002_pmic_201000236
crossref_primary_10_1080_08830180701402496
crossref_primary_10_1002_pmic_201200016
crossref_primary_10_1007_s11306_014_0659_5
crossref_primary_10_1152_ajprenal_00460_2019
crossref_primary_10_1089_ars_2014_5854
crossref_primary_10_1515_oncologie_2024_0074
crossref_primary_10_1002_elps_201000588
crossref_primary_10_1007_s00432_010_0778_y
crossref_primary_10_1007_s11481_009_9156_4
crossref_primary_10_1002_pmic_200700619
crossref_primary_10_1016_j_cmet_2018_04_009
crossref_primary_10_1111_j_1349_7006_2008_00799_x
crossref_primary_10_1155_2013_109285
crossref_primary_10_3389_fmed_2021_657313
crossref_primary_10_3724_abbs_2022189
crossref_primary_10_1016_j_yexmp_2016_11_003
crossref_primary_10_1038_cddis_2014_545
crossref_primary_10_18632_oncotarget_380
crossref_primary_10_3892_ijo_2021_5286
crossref_primary_10_1186_gb_2010_11_11_r115
crossref_primary_10_1111_febs_13535
crossref_primary_10_3233_KCA_170014
crossref_primary_10_1007_s10620_008_0665_4
crossref_primary_10_18632_oncotarget_1529
crossref_primary_10_1016_j_jpba_2019_112905
crossref_primary_10_1038_s41388_018_0315_z
crossref_primary_10_1155_2020_1932948
crossref_primary_10_1002_mas_20338
crossref_primary_10_1186_s13046_021_02103_5
crossref_primary_10_1586_epr_11_31
crossref_primary_10_3389_fonc_2020_570281
crossref_primary_10_1007_s00216_025_05741_2
crossref_primary_10_1016_j_gene_2015_12_058
crossref_primary_10_1016_j_jbior_2018_09_006
crossref_primary_10_1016_j_foodres_2021_110898
crossref_primary_10_1007_s12291_015_0481_5
crossref_primary_10_2174_0929867324666171006150326
crossref_primary_10_1007_s11306_019_1555_9
crossref_primary_10_2967_jnumed_113_134437
crossref_primary_10_3390_biom9030113
crossref_primary_10_1074_mcp_M800252_MCP200
crossref_primary_10_3390_diseases4010007
crossref_primary_10_1371_journal_pmed_1003786
crossref_primary_10_1007_s00216_018_1059_x
crossref_primary_10_1093_toxsci_kfn159
crossref_primary_10_1186_1476_4598_8_20
crossref_primary_10_1016_j_tranon_2017_06_002
crossref_primary_10_1373_clinchem_2012_184598
crossref_primary_10_1093_bioinformatics_btt285
crossref_primary_10_1111_j_1442_2042_2012_03221_x
crossref_primary_10_1093_bib_bbae498
crossref_primary_10_1016_j_bbrep_2022_101318
crossref_primary_10_1186_s12885_017_3184_x
crossref_primary_10_1089_scd_2007_0022
crossref_primary_10_1002_prca_200601048
crossref_primary_10_1093_qjmed_hcp071
crossref_primary_10_1038_s42003_024_06114_8
crossref_primary_10_1007_s00345_007_0199_y
crossref_primary_10_1590_S1677_5538_IBJU_2013_01_11
crossref_primary_10_1111_j_1476_5829_2012_00325_x
crossref_primary_10_3389_fonc_2019_00761
crossref_primary_10_1016_j_canlet_2017_10_031
crossref_primary_10_1021_pr500750z
crossref_primary_10_1186_1476_4598_6_16
crossref_primary_10_1093_bioinformatics_btr269
crossref_primary_10_1002_pmic_201000485
crossref_primary_10_1186_gb_2008_9_12_r179
crossref_primary_10_1371_journal_pone_0071654
crossref_primary_10_1021_acs_jproteome_0c00663
crossref_primary_10_1038_bjc_2015_322
crossref_primary_10_1186_s12920_020_00827_5
crossref_primary_10_1002_pmic_201200204
crossref_primary_10_1177_1010428317719780
crossref_primary_10_1016_j_clinbiochem_2012_11_029
crossref_primary_10_1039_C4MB00300D
crossref_primary_10_1155_2020_5974350
crossref_primary_10_6000_2292_2598_2019_07_02_3
crossref_primary_10_1016_j_bmc_2021_116129
crossref_primary_10_1158_0008_5472_CAN_14_1703
crossref_primary_10_1155_2015_313740
crossref_primary_10_1016_j_drudis_2024_103980
crossref_primary_10_1016_j_fct_2009_02_003
crossref_primary_10_1111_jcmm_13132
crossref_primary_10_3390_ijms18020294
crossref_primary_10_1371_journal_pone_0021867
crossref_primary_10_3389_fendo_2024_1429159
crossref_primary_10_1002_jso_21831
crossref_primary_10_4065_mcp_2009_0709
crossref_primary_10_1021_pr2005555
crossref_primary_10_1186_s12864_015_1768_x
crossref_primary_10_1534_g3_118_200297
crossref_primary_10_1186_s40001_021_00482_1
crossref_primary_10_3389_fonc_2019_00957
crossref_primary_10_1002_jssc_201400044
crossref_primary_10_3390_cancers16010022
crossref_primary_10_1038_nrneph_2017_59
crossref_primary_10_1080_15287394_2010_511545
crossref_primary_10_18632_oncotarget_9615
crossref_primary_10_1016_j_trsl_2016_07_018
crossref_primary_10_1002_pmic_200700415
crossref_primary_10_1021_acs_chemrestox_6b00187
crossref_primary_10_1074_mcp_M700273_MCP200
crossref_primary_10_4155_bio_11_326
crossref_primary_10_1080_10618600_2012_738614
crossref_primary_10_1016_j_jpba_2020_113752
crossref_primary_10_1158_0008_5472_CAN_11_3266
crossref_primary_10_18632_oncoscience_128
crossref_primary_10_3390_cells11193078
crossref_primary_10_1021_acs_jproteome_6b00875
crossref_primary_10_1371_journal_pone_0010696
crossref_primary_10_1517_17460441003716796
crossref_primary_10_1038_s41467_023_37211_7
crossref_primary_10_1016_j_ab_2007_01_028
crossref_primary_10_1586_14789450_5_1_29
crossref_primary_10_3389_fmolb_2021_763902
crossref_primary_10_15252_embj_201386874
crossref_primary_10_3892_ol_2016_5485
crossref_primary_10_1016_j_isci_2024_110357
crossref_primary_10_1111_jcmm_15536
crossref_primary_10_3389_fonc_2023_1164266
crossref_primary_10_1016_j_transci_2021_103079
crossref_primary_10_1039_C7MB00462A
crossref_primary_10_1038_nrneph_2011_152
crossref_primary_10_1038_bjc_2014_24
crossref_primary_10_1158_1055_9965_EPI_13_0584
crossref_primary_10_1021_acs_jmedchem_9b00598
crossref_primary_10_1007_s00467_016_3439_9
crossref_primary_10_1093_annonc_mdw241
crossref_primary_10_1152_ajprenal_00722_2009
crossref_primary_10_3109_1061186X_2012_736998
crossref_primary_10_1016_j_aca_2018_01_055
crossref_primary_10_1017_cts_2022_18
crossref_primary_10_3390_metabo13020299
crossref_primary_10_1038_emboj_2011_158
crossref_primary_10_1002_prca_200900157
crossref_primary_10_1586_14737159_2015_1028372
crossref_primary_10_18632_aging_102407
crossref_primary_10_1186_s12859_018_2157_7
crossref_primary_10_1371_journal_pone_0170453
crossref_primary_10_1016_j_semnephrol_2018_01_006
crossref_primary_10_1016_j_trac_2013_12_007
crossref_primary_10_1007_s11306_014_0758_3
crossref_primary_10_1111_j_1752_8062_2012_00437_x
crossref_primary_10_1021_pr101161u
crossref_primary_10_1002_jbt_23807
crossref_primary_10_1517_17425255_3_4_527
crossref_primary_10_1165_rcmb_2008_0353OC
crossref_primary_10_1186_s12014_020_09291_w
crossref_primary_10_1007_s11306_011_0319_y
Cites_doi 10.1093/emboj/18.5.1223
10.1001/jama.281.17.1628
10.1074/mcp.M500091-MCP200
10.1038/sj.ki.5000065
10.1007/s004320050175
10.1126/science.123.3191.309
10.1002/1615-9861(200205)2:5<561::AID-PROT561>3.0.CO;2-K
10.1016/S0898-6568(03)00136-0
10.1097/01.ju.0000154351.37249.f0
10.1152/ajpcell.1998.274.6.C1521
10.1002/pmic.200401134
10.1007/978-1-4615-5871-2_52
10.1002/1097-0215(20001015)88:2<191::AID-IJC7>3.0.CO;2-A
10.1023/A:1022494613613
10.1016/S0140-6736(06)68228-7
10.1007/s11306-005-1102-8
10.1073/pnas.95.4.1511
10.1681/ASN.2004070530
10.1073/pnas.80.4.901
10.1016/j.cell.2004.12.040
10.1097/01.ju.0000152354.08057.2a
10.1002/pmic.200401309
10.1073/pnas.171209998
10.1016/S1535-6108(03)00308-8
10.1093/nar/gki078
10.1016/j.exphem.2005.03.009
10.1007/s00262-006-0122-1
10.1073/pnas.84.6.1718
10.1002/pmic.200300464
ContentType Journal Article
Copyright Copyright © 2006 Perroud et al; licensee BioMed Central Ltd. 2006 Perroud et al; licensee BioMed Central Ltd.
Copyright_xml – notice: Copyright © 2006 Perroud et al; licensee BioMed Central Ltd. 2006 Perroud et al; licensee BioMed Central Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/1476-4598-5-64
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 64
ExternalDocumentID oai_doaj_org_article_166b9825d1f44be498588a71891fa758
PMC1665458
oai_biomedcentral_com_1476_4598_5_64
17123452
10_1186_1476_4598_5_64
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: 1R21CA 91259-01A1
– fundername: NIEHS NIH HHS
  grantid: P42 ES004699
– fundername: NIDDK NIH HHS
  grantid: R01 DK059470
– fundername: NIDDK NIH HHS
  grantid: R01DK59470
– fundername: NIEHS NIH HHS
  grantid: 2P42ES04699
GroupedDBID ---
0R~
123
29M
2VQ
2WC
4.4
53G
5VS
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BFQNJ
BMC
C6C
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
GROUPED_DOAJ
GX1
H13
HH5
HYE
IAO
IHR
INH
INR
IPNFZ
ITC
KQ8
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PZZ
RBZ
RIG
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
W2D
WOQ
WOW
XSB
-A0
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
FRP
NPM
7X8
ABVAZ
AFGXO
AFNRJ
5PM
ID FETCH-LOGICAL-b578t-4947846f2b2bf4d41603b74a48b6c6f6efacb6b40e4bdec50d7dce74a19f6e6f3
IEDL.DBID RBZ
ISSN 1476-4598
IngestDate Wed Aug 27 01:31:18 EDT 2025
Thu Aug 21 17:54:55 EDT 2025
Wed May 22 07:11:55 EDT 2024
Fri Jul 11 00:46:10 EDT 2025
Thu Jan 02 22:07:06 EST 2025
Thu Apr 24 22:55:46 EDT 2025
Tue Jul 01 04:34:39 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b578t-4947846f2b2bf4d41603b74a48b6c6f6efacb6b40e4bdec50d7dce74a19f6e6f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://dx.doi.org/10.1186/1476-4598-5-64
PMID 17123452
PQID 68196835
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_166b9825d1f44be498588a71891fa758
pubmedcentral_primary_oai_pubmedcentral_nih_gov_1665458
biomedcentral_primary_oai_biomedcentral_com_1476_4598_5_64
proquest_miscellaneous_68196835
pubmed_primary_17123452
crossref_primary_10_1186_1476_4598_5_64
crossref_citationtrail_10_1186_1476_4598_5_64
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2006-11-24
PublicationDateYYYYMMDD 2006-11-24
PublicationDate_xml – month: 11
  year: 2006
  text: 2006-11-24
  day: 24
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2006
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References Y Fan (196_CR12) 2003; 2
WH Chow (196_CR2) 1999; 281
RH Weiss (196_CR10) 2003; 4
F Thanner (196_CR20) 2005; 25
Y Dong (196_CR17) 2003; 16
WK Han (196_CR6) 2005; 16
C Gao (196_CR9) 2000; 88
RH Weiss (196_CR5) 2005
S Kress (196_CR13) 1998; 124
N Valkova (196_CR7) 2005; 4
SP Mathupala (196_CR24) 1997; 29
O WARBURG (196_CR31) 1956; 123
T Bando (196_CR30) 1997; 17
RH Weiss (196_CR33) 1998; 274
O Shvarts (196_CR3) 2005; 173
JB German (196_CR26) 2005; 1
JE Pawlowski (196_CR14) 2000; 20
RH Weiss (196_CR1) 2006; 69
HL Kim (196_CR4) 2005; 173
M Asada (196_CR11) 1999; 18
L Tremolada (196_CR22) 2005; 5
I Beuvink (196_CR16) 2005; 120
SM Bagnasco (196_CR27) 1987; 84
KM Bohren (196_CR29) 1997; 414
H Schepers (196_CR8) 2005; 33
C Falkensammer (196_CR15) 2006; 55
R Lichtenfels (196_CR19) 2002; 2
H Mi (196_CR35) 2005; 33
H Ashrafian (196_CR32) 2006; 367
N Valkova (196_CR34) 2006
JT Feng (196_CR21) 2005; 5
RD Unwin (196_CR23) 2003; 3
J Jeffery (196_CR28) 1983; 80
H Shim (196_CR25) 1998; 95
M Takahashi (196_CR18) 2001; 98
15711252 - J Urol. 2005 Mar;173(3):725-8
9696694 - Am J Physiol. 1998 Jun;274(6 Pt 1):C1521-9
16680201 - Metabolomics. 2005 Mar;1(1):3-9
15744000 - J Am Soc Nephrol. 2005 Apr;16(4):1126-34
9692838 - J Cancer Res Clin Oncol. 1998;124(6):315-20
9387094 - J Bioenerg Biomembr. 1997 Aug;29(4):339-43
15797377 - Cell. 2005 Mar 25;120(6):747-59
14706334 - Cancer Cell. 2003 Dec;4(6):425-9
16033076 - Anticancer Res. 2005 May-Jun;25(3A):1649-53
15608197 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D284-8
9465046 - Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1511-6
11205254 - Anticancer Res. 2000 Nov-Dec;20(6B):4243-55
14636896 - Cell Signal. 2004 Feb;16(2):263-9
3104902 - Proc Natl Acad Sci U S A. 1987 Mar;84(6):1718-20
15682460 - Proteomics. 2005 Feb;5(3):788-95
6405381 - Proc Natl Acad Sci U S A. 1983 Feb;80(4):901-5
15872312 - Mol Cell Proteomics. 2005 Jul;4(7):1009-18
16810557 - Cancer Immunol Immunother. 2006 Oct;55(10):1228-37
12939467 - Mol Cancer Ther. 2003 Aug;2(8):773-82
11987130 - Proteomics. 2002 May;2(5):561-70
10235157 - JAMA. 1999 May 5;281(17):1628-31
12923786 - Proteomics. 2003 Aug;3(8):1620-32
13298683 - Science. 1956 Feb 24;123(3191):309-14
16408110 - Kidney Int. 2006 Jan;69(2):224-32
16713411 - Biochim Biophys Acta. 2006 Jun;1764(6):1007-20
9059651 - Adv Exp Med Biol. 1997;414:455-64
10064589 - EMBO J. 1999 Mar 1;18(5):1223-34
15911090 - Exp Hematol. 2005 Jun;33(6):660-70
15821467 - J Urol. 2005 May;173(5):1496-501
11493696 - Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9
9413170 - Anticancer Res. 1997 Sep-Oct;17(5A):3345-8
16488806 - Lancet. 2006 Feb 18;367(9510):618-21
17162001 - J Urol. 2007 Jan;177(1):63-8; discussion 68-9
16240287 - Proteomics. 2005 Nov;5(17):4581-8
11004667 - Int J Cancer. 2000 Oct 15;88(2):191-4
References_xml – volume: 18
  start-page: 1223
  year: 1999
  ident: 196_CR11
  publication-title: EMBO J
  doi: 10.1093/emboj/18.5.1223
– volume: 281
  start-page: 1628
  year: 1999
  ident: 196_CR2
  publication-title: JAMA
  doi: 10.1001/jama.281.17.1628
– volume: 4
  start-page: 1009
  year: 2005
  ident: 196_CR7
  publication-title: Mol Cell Proteomics
  doi: 10.1074/mcp.M500091-MCP200
– volume: 69
  start-page: 224
  year: 2006
  ident: 196_CR1
  publication-title: Kidney Int
  doi: 10.1038/sj.ki.5000065
– volume: 2
  start-page: 773
  year: 2003
  ident: 196_CR12
  publication-title: Mol Cancer Ther
– volume: 124
  start-page: 315
  year: 1998
  ident: 196_CR13
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s004320050175
– volume: 123
  start-page: 309
  year: 1956
  ident: 196_CR31
  publication-title: Science
  doi: 10.1126/science.123.3191.309
– volume: 2
  start-page: 561
  year: 2002
  ident: 196_CR19
  publication-title: Proteomics
  doi: 10.1002/1615-9861(200205)2:5<561::AID-PROT561>3.0.CO;2-K
– volume: 16
  start-page: 263
  year: 2003
  ident: 196_CR17
  publication-title: Cell Signal
  doi: 10.1016/S0898-6568(03)00136-0
– volume: 173
  start-page: 1496
  year: 2005
  ident: 196_CR4
  publication-title: J Urol
  doi: 10.1097/01.ju.0000154351.37249.f0
– volume: 274
  start-page: C1521
  year: 1998
  ident: 196_CR33
  publication-title: Am J Physiol
  doi: 10.1152/ajpcell.1998.274.6.C1521
– volume: 5
  start-page: 788
  year: 2005
  ident: 196_CR22
  publication-title: Proteomics
  doi: 10.1002/pmic.200401134
– volume: 414
  start-page: 455
  year: 1997
  ident: 196_CR29
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-1-4615-5871-2_52
– volume: 88
  start-page: 191
  year: 2000
  ident: 196_CR9
  publication-title: Int J Cancer
  doi: 10.1002/1097-0215(20001015)88:2<191::AID-IJC7>3.0.CO;2-A
– volume: 29
  start-page: 339
  year: 1997
  ident: 196_CR24
  publication-title: J Bioenerg Biomembr
  doi: 10.1023/A:1022494613613
– volume: 367
  start-page: 618
  year: 2006
  ident: 196_CR32
  publication-title: Lancet
  doi: 10.1016/S0140-6736(06)68228-7
– volume-title: J Urol
  year: 2005
  ident: 196_CR5
– volume: 20
  start-page: 4243
  year: 2000
  ident: 196_CR14
  publication-title: Anticancer Res
– volume: 1
  start-page: 3
  year: 2005
  ident: 196_CR26
  publication-title: Metabolomics
  doi: 10.1007/s11306-005-1102-8
– volume-title: Biochim Biophys Acta
  year: 2006
  ident: 196_CR34
– volume: 17
  start-page: 3345
  year: 1997
  ident: 196_CR30
  publication-title: Anticancer Res
– volume: 95
  start-page: 1511
  year: 1998
  ident: 196_CR25
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.95.4.1511
– volume: 16
  start-page: 1126
  year: 2005
  ident: 196_CR6
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2004070530
– volume: 80
  start-page: 901
  year: 1983
  ident: 196_CR28
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.80.4.901
– volume: 120
  start-page: 747
  year: 2005
  ident: 196_CR16
  publication-title: Cell
  doi: 10.1016/j.cell.2004.12.040
– volume: 173
  start-page: 725
  year: 2005
  ident: 196_CR3
  publication-title: J Urol
  doi: 10.1097/01.ju.0000152354.08057.2a
– volume: 5
  start-page: 4581
  year: 2005
  ident: 196_CR21
  publication-title: Proteomics
  doi: 10.1002/pmic.200401309
– volume: 98
  start-page: 9754
  year: 2001
  ident: 196_CR18
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.171209998
– volume: 4
  start-page: 425
  year: 2003
  ident: 196_CR10
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(03)00308-8
– volume: 25
  start-page: 1649
  year: 2005
  ident: 196_CR20
  publication-title: Anticancer Res
– volume: 33
  start-page: D284
  year: 2005
  ident: 196_CR35
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gki078
– volume: 33
  start-page: 660
  year: 2005
  ident: 196_CR8
  publication-title: Exp Hematol
  doi: 10.1016/j.exphem.2005.03.009
– volume: 55
  start-page: 1228
  year: 2006
  ident: 196_CR15
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-006-0122-1
– volume: 84
  start-page: 1718
  year: 1987
  ident: 196_CR27
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.84.6.1718
– volume: 3
  start-page: 1620
  year: 2003
  ident: 196_CR23
  publication-title: Proteomics
  doi: 10.1002/pmic.200300464
– reference: 15911090 - Exp Hematol. 2005 Jun;33(6):660-70
– reference: 12939467 - Mol Cancer Ther. 2003 Aug;2(8):773-82
– reference: 16680201 - Metabolomics. 2005 Mar;1(1):3-9
– reference: 9465046 - Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1511-6
– reference: 11493696 - Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9
– reference: 15682460 - Proteomics. 2005 Feb;5(3):788-95
– reference: 15797377 - Cell. 2005 Mar 25;120(6):747-59
– reference: 9692838 - J Cancer Res Clin Oncol. 1998;124(6):315-20
– reference: 12923786 - Proteomics. 2003 Aug;3(8):1620-32
– reference: 14636896 - Cell Signal. 2004 Feb;16(2):263-9
– reference: 10064589 - EMBO J. 1999 Mar 1;18(5):1223-34
– reference: 9059651 - Adv Exp Med Biol. 1997;414:455-64
– reference: 11205254 - Anticancer Res. 2000 Nov-Dec;20(6B):4243-55
– reference: 16033076 - Anticancer Res. 2005 May-Jun;25(3A):1649-53
– reference: 6405381 - Proc Natl Acad Sci U S A. 1983 Feb;80(4):901-5
– reference: 15821467 - J Urol. 2005 May;173(5):1496-501
– reference: 16240287 - Proteomics. 2005 Nov;5(17):4581-8
– reference: 11004667 - Int J Cancer. 2000 Oct 15;88(2):191-4
– reference: 15608197 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D284-8
– reference: 9387094 - J Bioenerg Biomembr. 1997 Aug;29(4):339-43
– reference: 16810557 - Cancer Immunol Immunother. 2006 Oct;55(10):1228-37
– reference: 15744000 - J Am Soc Nephrol. 2005 Apr;16(4):1126-34
– reference: 16488806 - Lancet. 2006 Feb 18;367(9510):618-21
– reference: 9696694 - Am J Physiol. 1998 Jun;274(6 Pt 1):C1521-9
– reference: 15872312 - Mol Cell Proteomics. 2005 Jul;4(7):1009-18
– reference: 9413170 - Anticancer Res. 1997 Sep-Oct;17(5A):3345-8
– reference: 16408110 - Kidney Int. 2006 Jan;69(2):224-32
– reference: 10235157 - JAMA. 1999 May 5;281(17):1628-31
– reference: 11987130 - Proteomics. 2002 May;2(5):561-70
– reference: 15711252 - J Urol. 2005 Mar;173(3):725-8
– reference: 3104902 - Proc Natl Acad Sci U S A. 1987 Mar;84(6):1718-20
– reference: 16713411 - Biochim Biophys Acta. 2006 Jun;1764(6):1007-20
– reference: 13298683 - Science. 1956 Feb 24;123(3191):309-14
– reference: 14706334 - Cancer Cell. 2003 Dec;4(6):425-9
– reference: 17162001 - J Urol. 2007 Jan;177(1):63-8; discussion 68-9
SSID ssj0017874
Score 2.278863
Snippet Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US. Approximately one-third of...
BACKGROUND: Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US. Approximately...
Abstract Background Renal cell carcinoma (RCC) is the sixth leading cause of cancer death and is responsible for 11,000 deaths per year in the US....
SourceID doaj
pubmedcentral
biomedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 64
SubjectTerms Adult
Aged
Biomarkers, Tumor - analysis
Biomarkers, Tumor - urine
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - pathology
Electrophoresis, Gel, Two-Dimensional
Female
Gene Expression Profiling
Heat-Shock Proteins - metabolism
HSP27 Heat-Shock Proteins
Humans
Kidney Neoplasms - metabolism
Kidney Neoplasms - pathology
Male
Mass Spectrometry
Neoplasm Proteins - analysis
Neoplasm Proteins - metabolism
Neoplasm Proteins - urine
Proteomics - methods
Pyruvate Kinase - metabolism
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxUxFA6lUHEjtvUx1kcWgqvQyXhyMulOxVIKLV1Y6C7kNXrxOlfaW-T-e08yc2unKm7cJgcmyflO8mWSfIex17SI1U30KEI0ThBCkGIu1AIizch10s6UZBMnp3h0DscX6uJWqq98J2yQBx4Gbl8iekPbmCg7AJ_AtKptHc2oRnaOyG6efWnNW2-mxvMDgmE5TwaNApRpR7lG2eL-TZlQAu--c59Plqei4v8n6nn3BuWtJenwIXswckn-bujDNttI_Q7bGrJLrnbYvZPx3HyXHZ8R0fvhVtyNGiR80fGvs9inFQ_Z75c8X4D_zItsQ36ofEWmkX9LSwLJfBb4kNubTB6x88OPnz4ciTGLgvAUjUsBBjSRjK7xTb6UBzmvtNfgoPUYsMPUueDRQ53AxxRUHTV1iwykoUrs3j5mm_2iT08Z18YE1HUyjoheJBfUKjjvUoh1kCbFih1MBtN-HxQzbNawntZQONnsCZs9YZVFqJhYj7wNoz55TpMxt2Wf0uJv9m9u7Nff-Zvl--zISWtKAeHMjjiz_8JZxV6tYWApAvOxiuvT4vrKIpEqJCJbsScDKH41RxMvANVUTE_gMmnJtKaffSka3zJnhVbts__R9D12v_w4klI08JxtLi-v0wuiUkv_skTNTyNTGx0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagCNQLggJtePqAxMkQh4kflRACRFVVWsSBlXqz_Eq76pKF3a1g_33HTpYlbblxjSfKxJ7JfJOx5yPkJQaxsgpOMB-0ZWghAn3OlwwCfpHLKK3OZBOjL-JwDEfH9fFm_1M_gYtrU7vEJzWeT1___rl6jw7_Lju8Em84SMGg1orVTMBNcgujkkxsBiPYVBTQMHOFeS3bN3C8ev-lk-_TQcDKff2vA6OX91T-FaQO7pG7PbqkHzpzuE9uxHaH3O74Jlc75M6or6Q_IEdfEfr9sitq-64kdNbQs0lo44r6ZAlzmrbEn9DcyCEdXV6gaKDf4xLNZjrxtGP7RpGHZHzw-dunQ9bzKjCH_rlkoEEi7GgqV6VtepCYpp0EC8oJLxoRG-udcFBGcCH6ugwSXwsFuMZB0bx9RLbaWRv3CJVaeyHLqC1Cv8CVLmtvnY0-lJ7rGAqyP5hM86ProWFSV-vhCDqYSSth0kqY2ggoCFvPvPF9x_JEnDE1OXNR4or8qz_y6-f8S_JjWsiBNvnCbH5iepc1XAinMYEOvAFwEbSqlbIYyzVvLKZZBXmxNgODPpkKLbaNs_OFEQizBELbgux2RrFRRyJSgLoqiByYy0CT4Ug7Oc1dv3niia7V4_-h-hOynX8lcc4qeEq2lvPz-AzB1dI9z15zASQQImY
  priority: 102
  providerName: Scholars Portal
Title Pathway analysis of kidney cancer using proteomics and metabolic profiling
URI https://www.ncbi.nlm.nih.gov/pubmed/17123452
https://www.proquest.com/docview/68196835
http://dx.doi.org/10.1186/1476-4598-5-64
https://pubmed.ncbi.nlm.nih.gov/PMC1665458
https://doaj.org/article/166b9825d1f44be498588a71891fa758
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BKxAXBOXR5bH4gMTJIg4Tx-a2RVTVSouQoFLFxfIrdMWSrdqt0P57xk62JVs4cckhniiOZyb-xmN_A_CaJrGiDE5yH7TlZCGSfM4XHAP9kYtYW52LTcw-yaNjnJ5UJ9frHVsZfKHkW4G15FhpxSsu8TbslkjhXIrLD75d5QvI7HL-eCPb0zPefH7rXPtiMB1l1v6_Qc3tHZN_TEGHD-B-jx3ZpFP2Q7gV2z2401WTXO_B3VmfJ38E088E7H7ZNbM95whbNuzHPLRxzXzS8zlLG96_s0zTkA4mX5BoYD_jioxiMfesq-VNIo_h-PDj1w9HvK-awB1534qjxppARVO6Mm3Cw1RH2tVoUTnpZSNjY72TDouILkRfFaGmzyIBoalRNu-ewE67bOM-sFprL-siakvALgili8pbZ6MPhRc6hhG8HwymOesYMkzirB62kPuYpAmTNGEqI3EEfDPyxvd85KksxsLkuETJG_JvruQ37_mX5EFS5KA3-QaZlekd0ggpnabwOIgG0UXUqlLK0kytRWMpiBrBq40ZGPK4lEaxbVxeXhhJIEoScB3B084orrtTEw7AqhxBPTCXQU-GLe38NHN6i1QFulLP_mdEn8O9vEAkBC_xBeyszi_jS4JMKzeG3clk-mU6zksOdJ2hGmcP-g3EShed
linkProvider BioMedCentral
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BEY8LgvIKr_qAxMkQBz9ibhRRLaVbcWiliovlV8qKbRZtt0L77xk7SWlaOHGNJ4o9nvF8jj3fALzCIFZWwUnqg7YULUSiz_mS8oArchmV1bnYxHRfTg757pE46imFUi7MyVAU1qdBL99cTEKf55V7uDDW-Xst3zKuJOVC11RQya_DDSWEyqlc29_ODxTQLvMB8yDb8zdeff9S4vt8FK8yrf_fsOjlK5UXYtTOPbjbg0vyoev7fbgW20242ZWbXG_CrWl_kP4Adr8i8vtl18T2pCRk0ZAfs9DGNel0QtKN-GOSeRxS5vIpigZyEldoNfOZJ12xbxR5CIc7nw4-TmhfVoE6dM8V5ZorRB1N5ap0S4-nQtNOcctrJ71sZGysd9LxMnIXohdlUDgsFGAaG2Xz7hFstIs2PgGitPZSlVFbRH6B1boU3jobfSg90zEU8H6kTPOzo9AwidR63IJTa9JMmDQTRhjJC6CD5o3vCctT3Yy5yRuXWl6Rf30uP3znX5LbaSJHvckPFstj09uXYVI6jfvnwBrOXeS6FnVtMZRr1ljcZRWwNZiBQZdM5yy2jYuzUyMRZUlEtgU87oziT3cUAgUuqgLUyFxGPRm3tLPvmfSbpTLRon76PxrdgtuTg-me2fu8_-UZ3Ml_kxijFX8OG6vlWXyB-GrlXmbP-Q0lcCS2
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BEVUvCMpry6M-IHEyjYMfMTcKrEqhVYWoVHGx_EpZdZuttluh_feMnaQ0LZy4RfFEsT0zmc_xeD6AVxjEijI4SX3QlqKFSPQ5X1Ae8ItcRGV1JpvY25c7h3z3SBx1-U_pLMxpTwrr06Dnb64eQp_mLzde-JOts1C3Dl_JLcaVpFzoigoq-W24o4RQic3g2_aPyx0FNMy8w9zLdgUcbz5_7eT7dBCwcl3_v4HR6zmVV4LU-D7c69Aled-awwO4FZt1uNvyTS7XYXWv20l_CLsHCP1-2SWxXVUSMqvJySQ0cUnaSSEpJf6Y5EIO6ejyOYoGchoXaDbTiSct2zeKPILD8afvH3Zox6tAHfrngnLNFcKOunRlStPjiWnaKW555aSXtYy19U46XkTuQvSiCAqHhQJMY6Os3z6GlWbWxKdAlNZeqiJqi9AvsEoXwltnow-FZzqGEbwbTKY5a2tomFTVetiCujVJEyZpwggj-QhoP_PGdxXLE3HG1OSVSyVvyL--lO_f8y_J7aTIQW_yjdn82HQua5iUTuMCOrCacxe5rkRVWYzlmtUWl1kj2OzNwKBPpo0W28TZxbmRCLMkQtsRPGmN4k93FCIFLsoRqIG5DHoybGkmP3PVb5Z4okW18T8zugmrBx_H5uvn_S_PYC3_TWKMlvw5rCzmF_EF4quFe5kd5zee0CSB
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pathway+analysis+of+kidney+cancer+using+proteomics+and+metabolic+profiling&rft.jtitle=Molecular+cancer&rft.au=Fiehn+Oliver&rft.au=Lin+Pei-Yin&rft.au=Dhirapong+Amy&rft.au=Valkova+Nelly&rft.date=2006-11-24&rft.pub=BMC&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=5&rft.issue=1&rft.spage=64&rft_id=info:doi/10.1186%2F1476-4598-5-64&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_166b9825d1f44be498588a71891fa758
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon